NCT06304779 The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI
| NCT ID | NCT06304779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Postoperative Pulmonary Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 428 participants |
| Start Date | 2023-10-31 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 428 participants in total. It began in 2023-10-31 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to evaluate the impact of continuous 24-hour intravenous infusion of lidocaine on the incidence of PPCs in patients undergoing emergency laparotomy for intra-abdominal infection (IAI).The secondary objectives of this study are to assess the impact of continuous 24-hour intravenous lidocaine infusion on the proportion of patients requiring mechanical ventilation, protection of important organ function during the perioperative period, length of hospital stay, and outcomes within 30 days postoperatively.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years, any gender. * Patients suspected of digestive tract perforation or obstruction based on physical examination, confirmed by imaging, requiring emergency surgical treatment. * The anesthesia method is general anesthesia * I or the patient's family have carefully read and signed the informed consent form * Serum procalcitonin (PCT) at inflammatory levels or leukocytosis (\>12×109/L) or leukopenia (\<4×109/L) or \>10% naive leukocytes Exclusion Criteria: * Have a history of local anesthesia drug allergy * Pregnant patients * Patients receiving renal replacement therapy * Patients with arrhythmias or heart failure (second or third-degree atrioventricular block or left ventricular ejection fraction（LVEF） * Preoperative platelet count\<80 × 109/L * Patients who require secondary surgery for postoperative anastomotic fistula * Patients who have participated in other clinical studies
Frequently Asked Questions
Who can join the NCT06304779 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Postoperative Pulmonary Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06304779 currently recruiting?
Yes, NCT06304779 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Zhongshan Hospital to inquire about joining.
Where is the NCT06304779 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06304779 clinical trial?
NCT06304779 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 428 participants.